United States
Former CIA director John Brennan's transition to private sector threatened with legal action by his shareholders
ImmunityBio's shares have plunged by more than half after the FDA recently rejected approval of its cancer treatment, but its business prospects were already murky when Brennan joined the board. He also has positions at Kissinger Associates and WestExec Advisors, dubbed President's Joe Biden's 'Cabinet in Waiting' in the aftermath of his 2020 election.